Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Plus Therapeutics (PSTV) reported financial results for Q4 and FY 2020, highlighting significant clinical advancements in the ReSPECT™ Phase 1 trial for recurrent glioblastoma. The company completed its sixth dosing cohort and showcased positive interim data, supported by a NIH/NCI grant. As of Dec 31, 2020, cash reserves stood at $8.3 million, down from $17.6 million the previous year. The net loss for 2020 was $8.2 million, improving from $11.4 million in 2019. Plus Therapeutics aims to advance its CNS oncology portfolio and expand its pipeline in 2021.
Plus Therapeutics (Nasdaq: PSTV) will report its fourth quarter and full year 2020 financial results on February 22, 2021, after market close. A conference call will follow at 5:00 PM ET for a discussion of the results and corporate update. The company focuses on developing targeted treatments for rare cancers utilizing nanotechnology to enhance drug delivery and efficacy. Interested parties can access a live webcast and subsequent replay on their investor relations website.
Plus Therapeutics (Nasdaq: PSTV) announced participation in the BIO CEO & Investor Digital Conference from February 16-18, 2021. CEO Marc Hedrick will present, with the presentation available on demand for registered attendees. Additionally, Plus Therapeutics was recognized as this year’s Public Therapeutic Company 'Buzz of BIO' for its innovative work in developing therapies for rare cancers like recurrent glioblastoma. The company focuses on nanoliposome-encapsulated radionuclide therapies designed to improve cancer treatment delivery and efficacy.
Plus Therapeutics (Nasdaq: PSTV) has announced that Marc Hedrick, M.D., CEO, will present at three upcoming virtual conferences in January 2021. The conferences are:
- H.C. Wainwright BioConnect Conference: January 11-14, 2021
- Biotech Showcase 2021: January 11-15, 2021
- ICR Conference 2021: January 14, 2021, at 1:45 p.m. ET
Plus Therapeutics (Nasdaq: PSTV) has completed the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial for Rhenium NanoLiposome (RNL™) in recurrent glioblastoma patients. This cohort included increased drug volume to 8.8 milliliters and radiation dose to 22.3 millicuries. Eighteen patients have been treated to date. RNL has received Orphan Drug and Fast Track designations from the FDA, enhancing its development status. No dose-limiting toxicities were observed in interim data, indicating a favorable safety profile.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc Hedrick, M.D., President and CEO, will present a company overview at the 13th Annual LD Micro Main Event Conference on December 14 at 10:40 a.m. ET. Investors can attend via a live webcast available on the event’s homepage. Additionally, an archived recording will be accessible later on Plus Therapeutics' website. The company focuses on developing innovative treatments using nanotechnology targeting rare cancers, enhancing safety and efficacy for patients.
Plus Therapeutics (PSTV) has announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site for its ReSPECT™ Phase 1 clinical trial. This trial investigates the company's lead candidate, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The trial is supported by the National Cancer Institute. The sixth dose escalation cohort is currently underway, with enrollment expected to complete by the end of 2020. RNL has also received Orphan Drug and Fast Track designations from the FDA for glioblastoma treatment.
Plus Therapeutics (Nasdaq: PSTV) announced positive interim results from its ReSPECT™ Phase 1 trial of Rhenium NanoLiposome (RNL™) for treating recurrent glioblastoma (GBM). The trial demonstrated RNL's ability to deliver up to 15 times the radiation dose compared to standard external beam therapy, with no significant toxicity observed. All 15 patients in initial cohorts completed treatment, showing promising survival rates, particularly among those not previously treated with bevacizumab. The trial is advancing to its sixth dose escalation cohort, supported by FDA's Orphan Drug and Fast Track designations.
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced participation in two virtual investor conferences. The first is the Virtual Fall Investor Summit on November 17, 2020, at 3:00 p.m. ET, followed by the A.G.P. Virtual Healthcare Symposium on November 19, 2020. Investors can arrange virtual 1x1 meetings with management. A live webcast of the first summit will be available on the company’s website. Plus Therapeutics focuses on innovative radiotherapeutic solutions for cancer treatment using a unique nanotechnology platform.
Plus Therapeutics (PSTV) will host a webinar on November 19, 2020, discussing interim data from the ReSPECT Phase 1 clinical trial for Rhenium NanoLiposome (RNL) in treating recurrent glioblastoma (GBM). The company recently received Orphan Drug and Fast Track designations from the FDA for RNL. The webinar will detail interim findings regarding safety, tolerability, and efficacy, presented by Dr. Andrew Brenner, a key figure in the trial. The ReSPECT trial aims to fully enroll by the end of 2020, highlighting a significant step in addressing the unmet medical needs in GBM treatment.